ARMS Medical, a supplier of advanced surgical technologies and tools, and Tissue Regenix BioSurgery, an international medical technology company, have entered into an exclusive distributor agreement for DermaPure dermal allograft. The multi-year agreement gives ARMS Medical exclusive rights to distribute the Tissue Regenix biologic to hospitals and surgeons throughout the United States for use in urology and gynecology procedures.
 
David Pennington, vice president of sales for Tissue Regenix BioSurgery, stated, “We chose ARMS Medical as our exclusive distributor because of their strong relationships with key opinion leaders in the urogyn space. Additionally, they are known for bringing innovation to women’s pelvic health solutions. ARMS Medical has helped us extend the use of DermaPure into pelvic floor surgery which could open the opportunity for a more novel approach compared to existing technologies. Together, we are providing education and onboarding for surgeons with the goal of improving patient outcomes and satisfaction.”
 
Rob Greer, Founder of ARMS Medical, commented “Our partnership with Tissue Regenix is advancing the treatment options for pelvic floor surgery. We believe DermaPure allograft is the optimal solution for repairing pelvic organ prolapse and other conditions, and it is a key component of our suite of innovative products. This distribution agreement will empower ARMS Medical to expand adoption of DermaPure by hospitals and surgeons for the benefit of women.”
 
DermaPure is a next-generation decellularized dermal allograft processed with patented dCELL technology. The dCELL process creates a bio-inductive scaffold resulting from to the removal of DNA and cellular material from biological tissues, DermaPure enables the patient's cells to repopulate and colonize, creating new tissue that is recognized and accepted by the body and stimulates a natural healing process.
 
According to James Lukban, D.O., FACOG, FACS, FFPMRS, a Colorado-based urogynecologic surgeon, “Since learning about DermaPure from ARMS Medical, I have been very impressed by its advantages over other technologies and competitive biologics. It offers good handling characteristics, is easy to place, incorporates well into surrounding tissue and has a negligible exposure rate. The proprietary dCELL technology promotes tissue growth and healing more effectively than cross-linked products. and I continue to advocate strongly for its use in pelvic organ prolapse and surgical repair.”
 
Tissue Regenix develops regenerative medicine technology. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, United Kingdom. The company's patented decellularisation (dCELL) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
 
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States—'Tissue Regenix Wound Care Inc.' January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.In August 2017 Tissue Regenix acquired CellRight Technologies, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care sc affolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
 
ARMS Medical provides advanced surgical technologies and tools for pelvic floor issues, including organ prolapse and incontinence. ARMS Medical supplies a suite of products to the healthcare industry, including DermaPure allograft, StitchKit suturing technology, Smoke Evacuation Pencil and Veronikis Vaginal Retractor System.